ILMN
ILLUMINA, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$227.23
−4.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$242.31
From 52W high−22.63%
Volume1.39M
Market cap$34.36B
P/E (TTM)38.6x
P/S (TTM)7.6x
Div yield—
Key dataNov 4, 2026
Open
$242.31
From 52W high
−22.63%
Volume
1.39M
Market cap
$34.36B
ValuationView details →
P/E (Fwd)
38.1x
EV/EBITDA
25.5x
P/E (TTM)
38.6x
RSI (14)
37.6
MomentumView details →
1D Return
−4.61%
YTD Return
+71.93%
SummaryUpdated Sep 1, 2026
Illumina, Inc. (NASDAQ:ILMN) is a leading biotechnology company founded in 1998 and based in San Diego, California, that went public in 2000. The company pioneered the development of DNA sequencing and array-based solutions that have revolutionized genetic and genomic analysis. Over its 25+ year history, Illumina has established itself as the dominant player in the DNA sequencing market, providing the foundational technology that enables genomic research, clinical diagnostics, and personalized medicine applications worldwide.
Similar companies
Latest newsMore news →
Illumina was selected to provide whole-genome sequencing services for Singapore’s ILLUMINA, INC. study, which is expected to include around 450,000 people.2d agoILLUMINA, INC. reported quarterly earnings of $1.44 per share, compared with $1.34 per share a year earlier.6d agoIllumina reported third-quarter fiscal 2026 revenue of $1.13 billion, up 4.2% from the third quarter of 2025.6d ago